Form 4: Akero Therapeutics Executive Timothy Rolph Executes Stock Options and Sells Shares

Akero Therapeutics' Chief Scientific Officer, Timothy Rolph, exercised stock options and sold shares under a pre-arranged Rule 10b5-1 trading plan.

Summary

• On April 24, 2025, Timothy Rolph, Chief Scientific Officer of Akero Therapeutics, exercised stock options to acquire 6,250 shares of common stock at a price of $21.10 per share.
• Simultaneously, Rolph sold 6,250 shares of common stock at a weighted-average price of $41.03, with individual sales ranging from $41.00 to $41.12.
• These transactions were executed under a pre-arranged Rule 10b5-1 trading plan established on August 12, 2024.
• Following these transactions, Rolph directly owns 169,721 shares of Akero Therapeutics common stock.
• Rolph also holds 51,541 stock options.

Sentiment

Score: 5

Explanation: Neutral. This is a standard Form 4 filing, indicating routine transactions by an executive. It doesn't inherently suggest positive or negative sentiment about the company's prospects.

Industry Context

This filing is a routine disclosure of insider transactions. It's common for executives to have pre-arranged trading plans (Rule 10b5-1) to avoid accusations of trading on inside information. The market will likely interpret this as a standard executive compensation activity.

Stakeholder Impact

• The transactions may have a minor impact on shareholders due to the change in ownership, but the effect is likely minimal given the relatively small number of shares involved.
• Employees are unlikely to be directly affected by these transactions.

Key Dates

Keywords

Akero Therapeutics, Timothy Rolph, stock options, Rule 10b5-1, insider trading, AKRO, securities, common stock